However, few clinical studies have supported the therapeutic benefit of mGluR modulation in the management of psychiatric and neurological disorders, with the exception of a positive clinical trial for the mGluR2/3 agonist LY2140023 in the treatment of schizophrenia. Here, GRM2 is linked to schizophrenia.